High Cost Drugs Validation/ Blueteq® Management

NHS ML Validate service provides bespoke prescribing reports by validating high-cost drug usage with provider trusts against locally commissioned guidance and pathways. This service can significantly reduce administrative burden, improve financial control and provide commissioners and providers with the assurance that high-cost interventions are being used appropriately in their local health economy.  

Innovative software solutions developed by NHS ML have automated the Blueteq® validation process, reducing turnaround times and providing commissioners and providers with the flexibility to review incorrect charges. The same process presents NHS Trusts with the ability to recharge to the appropriate commissioner if invoicing errors are identified. Significantly, implementing Validate alongside the Blueteq® service can assist NHS Trusts to provide assurance that high-cost interventions are in line with NICE Technology Appraisals and local commissioning pathways.   

NHS ML Validate team can provide a complete service for commissioners, providing assurance that high-cost interventions are being used appropriately. The service includes:  

  • Automating high-cost drug or device data validation against local commissioning pathways in combination with the Blueteq® prior approval system   

  • Procuring and maintaining a contract for the Blueteq® system (optional – if not already in place)  

  • NHS ML Validate service screening tool can identify charges to the commissioning organisation without the need for the Blueteq® system   

  • Validation reports for commissioner financial and contractual negotiations  

  • NHS ML Validate service will also manage the dispute process (optional)   

  • All high-cost drug data handled by NHS ML Validate service is pseudonymised and supported by the appropriate governance approvals. 

For advice or to discuss how we can support your organisation, please contact our team at hcd.mlcsu@nhs.net.